...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Presentation slides are up
3
Jun 18, 2020 10:59AM

"Lots of irons in the fire with potential partners to pay for future trial costs while Zenith receiving non-refundable ROFR payments, milestone payments and royalty payments."

If I'm hearing this correctly this call seems to be directed at Pfizer saying, if you don't want the compitition of other companies take us out now or soon.

DM said a lot more on that call than I was expecting.

tada 

Share
New Message
Please login to post a reply